US SEC Filings Daily Market Digest — July 30, 2026

30-07-2026

Braveheart Bio, Inc. filed Amendment No. 1 to its S-1 registration statement on July 30, 2026, for an initial public offering of 18,750,000 shares of common stock, with an estimated price range of $15.00 to $17.00 per share. The company is a clinical-stage biopharmaceutical firm focused on hypertrophic cardiomyopathy therapies, with lead candidate BHB-1893 in-licensed from Hengrui. While the offering targets up to $75 million from a cornerstone investor (Fidelity), the company has no public market for its stock, is pre-revenue, and faces significant risks including reliance on a single product candidate and clinical trial data generated by a third party.

• · The company has applied to list on Nasdaq under the symbol 'BRVE'.
• · Braveheart is an 'emerging growth company' and a 'smaller reporting company' and has elected reduced reporting requirements.
• · All clinical trials of BHB-1893 completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial in Australia; Braveheart was not involved in their design, conduct, or oversight.
• · BHB-1893 is designed to address limitations of first-generation CMIs, including rapid onset, predictable pharmacokinetics, limited drug-drug interactions, and low LVEF cost.
• · The underwriters have a 30-day option to purchase up to an additional 2,812,500 shares.
• · The offering is contingent upon listing on Nasdaq.

30-07-2026

CRH reported net income of $1,511M for Q2 2026, up 13.4% from $1,332M in Q2 2025, and $1,331M for H1 2026, up 7.9% from $1,234M in H1 2025. Total revenues rose 5.6% to $10,777M in Q2 and 7.0% to $18,147M in H1. However, comprehensive income attributable to CRH fell 17.8% in Q2 to $1,463M and 36.8% in H1 to $1,191M, driven by a large currency translation loss of $102M in H1 versus a gain of $749M a year ago. Operating cash flow declined 28.7% to $513M in H1, while the company generated $1,676M in divestiture proceeds.

• · Americas Building Solutions revenue declined 1.9% in Q2 and 1.5% in H1, driven by a 5.8% drop in Outdoor Living Solutions to $1,551M in Q2 and a 4.9% drop to $2,748M in H1.
• · Operating cash flow fell 28.7% to $513M in H1 2026, primarily due to a $1,824M increase in accounts receivable (vs. $1,397M in H1 2025).
• · Cash and cash equivalents decreased 26.1% from $4,096M at Dec 31, 2025 to $3,025M at June 30, 2026.
• · The company generated $1,676M in proceeds from divestitures in H1 2026, compared to just $37M in H1 2025, and spent $1,110M on acquisitions (vs. $648M).
• · Long-term debt was reduced by 6.5% to $15,410M from $16,478M at year-end 2025.
• · Share repurchases totaled $607M in H1 2026, down from $644M in H1 2025; dividends paid increased to $521M from $500M.

30-07-2026

Yum China reported strong Q2 2026 results with revenue up 13% YoY to $3.1B and operating profit up 14% to $348M, marking the 9th consecutive quarter of OP margin expansion. Same-store sales grew 1% YoY (improving sequentially) with record net new store openings of 560 (up 67% YoY). However, Pizza Hut's restaurant margin declined 40 bps YoY to 12.9% due to higher delivery costs and value-for-money offerings, and KFC's restaurant margin was flat in the first half. The acquisition of the Pizza Hut brand in Mainland China is expected to close in August 2026.

• · Pizza Hut's same-store sales growth decelerated to 1% in Q2 2026 from 2% in Q2 2025.
• · Pizza Hut's restaurant margin declined 40 bps YoY to 12.9% in Q2 due to higher delivery costs, value-for-money offerings and investment in Pizza Hut Burger Bar.
• · KFC's restaurant margin in the first half of 2026 was flat year-over-year at 18.1%.
• · Delivery sales grew 26% YoY, contributing ~54% of total Company sales (up from 45%).
• · The Company targets total stores of over 20,000 by year-end 2026, with 40-50% franchise mix of net new stores.
• · Starting in 2027, the Company plans to return approximately 100% of annual free cash flow (after non-controlling interest dividends), anticipated to be ~$900M-$1B+ in 2027-2028.
• · The Pizza Hut brand acquisition in Mainland China is expected to close in August 2026, financed by an ~$1.2B offshore bridge loan.

30-07-2026

Mizuho Financial Group reported Q1 FY2026 results with total assets increasing to ¥304,283,463 million from ¥302,240,042 million at fiscal year-end 2025. Comprehensive income rose 25.8% to ¥413,801 million, while the company revised its full-year profit estimate upward by 7.6% to ¥1,400,000 million. However, the own capital ratio remained flat at 3.7%, and retained earnings declined slightly from ¥6,831,168 million to ¥6,777,359 million.

• · Cash and due from banks decreased from ¥61,567,751 million to ¥52,124,258 million.
• · Securities increased from ¥42,632,517 million to ¥49,922,242 million.
• · Loans and bills discounted increased from ¥99,753,193 million to ¥103,079,469 million.
• · Deposits slightly decreased from ¥165,937,062 million to ¥165,315,426 million.
• · Treasury stock decreased from ¥(311,529) million to ¥(51,070) million, indicating share buybacks.
• · Dividend per share estimate for fiscal 2026 is ¥150.00, up from ¥145.00 in fiscal 2025.

30-07-2026

Pharming Group N.V. reported a net loss of $3.6M for the first half of 2026, an improvement from a $10.3M loss in 1H 2025, driven by a 40% increase in Joenja revenue to $32.0M. However, total revenue declined 5.6% to $162.7M, primarily due to a 12.3% drop in RUCONEST sales to $130.7M, and operating profit swung to a loss of $3.6M from a profit of $3.8M a year earlier. The company ended the period with $158.3M in cash and cash equivalents, down from $145.3M at year-end 2025.

• · R&D expenses increased 28.9% to $57.8M in 1H 2026 from $44.8M in 1H 2025.
• · Marketing and sales expenses decreased 10.2% to $58.9M in 1H 2026 from $65.6M in 1H 2025.
• · General and administrative expenses decreased 29.8% to $30.2M in 1H 2026 from $43.0M in 1H 2025.
• · Net cash used in operating activities was $7.7M in 1H 2026 vs. $12.0M generated in 1H 2025.
• · Total assets decreased to $468.0M at June 30, 2026 from $500.0M at December 31, 2025.
• · Current liabilities decreased to $93.2M from $115.8M at year-end 2025.
• · Convertible bonds (non-current) stood at $92.4M, essentially flat vs. $92.7M at year-end 2025.

30-07-2026

Sumitomo Mitsui Trust Group, Inc. filed its quarterly 13F-HR for the period ending June 30, 2026, reporting approximately $175.06 billion in total holdings across a diversified portfolio of equities, ETFs, and ADRs. Major positions include Apple Inc. ($9.63B), Amazon.com Inc. ($5.95B), and Broadcom Inc. ($4.23B), with significant holdings also in Advanced Micro Devices ($2.84B) and Applied Materials ($1.36B). The filing reflects a broad, multi-manager strategy with holdings managed by subsidiaries including Sumitomo Mitsui Trust Bank, Amova Asset Management, and Sumitomo Mitsui Trust Asset Management.

• · The filing includes 1,080 reportable holdings with a total market value of $175,059,245,023.
• · Top holdings by value include Apple Inc. ($9.63B), Amazon.com Inc. ($5.95B), Broadcom Inc. ($4.23B), Advanced Micro Devices ($2.84B), and Applied Materials ($1.36B).
• · The filing is a combination report covering multiple managers: Sumitomo Mitsui Trust Bank, Amova Asset Management Co., Ltd., Sumitomo Mitsui Trust Asset Management Co., Ltd., Amova Asset Management UK Ltd, Amova Asset Management Asia Ltd, and AHAM Asset Management Berhad.
• · The report is signed by Hideaki Takamiya, Senior Manager of Risk Management Dept., on July 30, 2026.

30-07-2026

ASE Technology reported strong Q2 2026 results with net revenues of NT$126,148 million, up 36.3% YoY and 12.2% sequentially. Income before tax surged to NT$25,700 million from NT$18,161 million in Q1 2026, while basic EPS reached NT$4.80. However, raw material costs rose to 45% of net revenues (NT$86,253 million) from 28% in a prior period (NT$34,782 million), indicating a significant cost pressure.

• · Basic EPS for Q2 2026 was NT$4.80 (US$0.304 per ADS).
• · Diluted EPS for Q2 2026 was NT$4.61 (US$0.292 per ADS).
• · Labor cost was NT$21,920 million, representing 11% of net revenues.
• · Other net non-operating income was NT$484 million.
• · Cost of revenues increased 26.7% YoY and 10.1% sequentially.

30-07-2026

Virtu Financial reported Q2 2026 total revenues of $1,190.0 million, up 19.0% YoY, and Adjusted Net Trading Income of $717.9 million, up 26.4% YoY. However, GAAP net income declined to $284.9 million from $293.0 million in the prior-year quarter, and basic EPS slipped to $1.63 from $1.65, reflecting a mixed performance with strong top-line growth but lower profitability.

• · Board declared a quarterly cash dividend of $0.24 per share, payable September 15, 2026 to shareholders of record as of September 1, 2026.
• · Market Making segment total revenues were $1,009.2M in Q2 2026 vs $786.6M in Q2 2025; Execution Services segment total revenues were $173.5M vs $214.5M in Q2 2025 (a decline of 19.1%).
• · Execution Services segment Adjusted Net Trading Income was $138.0M in Q2 2026 vs $116.3M in Q2 2025, up 18.7%.
• · For the six months ended June 30, 2026, total revenues were $2,285.3M vs $1,837.4M in the prior year period.
• · Cash, cash equivalents and restricted cash totaled $1,133.0M; long-term debt was $2,051.1M as of June 30, 2026.

30-07-2026

Ambev reported mixed Q2 2026 results with consolidated net revenue up 6.1% YoY to R$20,148.9M and normalized EBITDA up 8.9% YoY to R$6,376.7M, driven by strong performance in Brazil (beer volume +5.0%, normalized EBITDA +12.8%). However, the CAC segment saw a volume decline of 5.4% and normalized EBITDA fell 4.9%, while Canada's volume dropped 1.8% and normalized EBITDA declined 2.9%. Net finance results improved significantly to a loss of R$486.1M from a loss of R$974.0M in 2Q25, primarily due to lower exchange losses.

• · Brazil beer volume grew 5.0% YoY to 21,034.9 thousand hl in Q2 2026, while Brazil NAB volume declined 4.4% to 7,615.3 thousand hl.
• · CAC segment volume declined 5.4% YoY to 2,659.4 thousand hl in Q2 2026, with net revenue down 7.1% and normalized EBITDA down 4.9%.
• · LAS segment volume declined 2.9% YoY to 6,015.0 thousand hl, with net revenue down 4.4% and normalized EBITDA down 2.6%.
• · Canada segment volume declined 1.8% YoY to 2,403.3 thousand hl, with net revenue down 2.1% and normalized EBITDA down 2.9%.
• · Net finance result improved to a loss of R$486.1M in Q2 2026 from a loss of R$974.0M in Q2 2025, driven by lower exchange differences (loss of R$141.2M vs R$527.5M) and lower losses on hedging instruments (R$167.2M vs R$276.3M).
• · Total assets decreased to R$138,209.0M as of June 30, 2026 from R$145,087.2M as of December 31, 2025.
• · Cash and cash equivalents decreased to R$16,610.8M from R$18,638.2M over the same period.
• · Equity attributable to Ambev's shareholders increased slightly to R$88,313.2M from R$87,914.0M.
• · The company will hold an earnings conference call on July 30, 2026 at 12:30 PM Brasília time.

30-07-2026

Magnum Ice Cream Co B.V. reported mixed H1 2026 results with total revenue growing 4.2% YoY to €4.691B and adjusted EBIT rising 7.5% to €716M. However, the overall adjusted EBITDA margin contracted 30bps to 18.7%, dragged down by a 70bps impact from Transitional Service Agreements and a 30bps impact from the India acquisition. Regional performance was uneven: Europe & ANZ delivered 4.1% organic sales growth with positive volume growth but negative price growth (-0.6%), Americas saw reported revenue decline of 1.1% with near-flat volume growth (0.1%), and AMEA reported strong 7.6% organic sales growth but with margin compression (adjusted EBITDA margin falling from 26.2% to 23.5%). Free cash flow nearly doubled to €273M from €138M.

• · H1 2026 diluted earnings per share: €0.55
• · H1 2026 adjusted earnings per share: €0.72
• · Europe & ANZ organic volume growth was 4.8% but organic price growth was -0.6% in H1 2026.
• · Americas organic volume growth was virtually flat at 0.1% in H1 2026 (Q2 2026 also 0.1%).
• · AMEA organic sales growth slowed from 10.7% in H1 2025 to 7.6% in H1 2026; organic volume growth decelerated sharply from 7.1% to 1.9%.
• · Total adjusting items increased to €129M in H1 2026 from €97M in H1 2025.
• · Depreciation and amortisation declined from €187M to €164M.

30-07-2026

ChipMOS Technologies Inc. reported strong financial results for May 2026 and Q1 2026, with revenue growing 17.7% YoY to NT$2,384 million in May and 25.4% YoY to NT$6,936 million in Q1. Net profit attributable to owners surged 174.1% YoY in May and 186.9% YoY in Q1, while EPS rose 175% and 200% respectively. However, the recent four-quarter accumulation shows a net profit margin of only 3.9%, indicating that profitability remains thin despite strong growth.

• · Trailing four-quarter (2025Q2-2026Q1) revenue was NT$25,336 million, net profit before tax NT$987 million, and profit attributable to owners NT$824 million.
• · EPS for the trailing four quarters was NT$1.17.
• · Net profit margin for the trailing four quarters was approximately 3.9% (NT$987M / NT$25,336M), indicating thin profitability despite strong growth.

30-07-2026

ING Groep N.V. filed a Form 6-K with the SEC on July 30, 2026, attaching a press release of the same date. The filing is a routine foreign issuer report for the month of July 2026, signed by Head of Media Relations Raymond Vermeulen. No financial figures or performance data are included in the filing itself, only a reference to the attached press release.

• · The filing is a Form 6-K (foreign private issuer report) for the month of July 2026.
• · The press release is dated July 30, 2026, and is attached as Exhibit 99.1.
• · The registrant's principal executive office is at Bijlmerdreef 106, 1102 CT Amsterdam, The Netherlands.

30-07-2026

Delixy Holdings Ltd announced the resignation of two independent directors, Lay Shi Wei and Yap Beng Tat Richard, effective July 29, 2026, and the appointment of two new independent directors, Zhang Chunming and Ye Changkun, effective July 30, 2026. The board committees were reconstituted accordingly. The resignations were not due to any disagreement with the company, and the board now consists of two executive and three independent directors.

• · The resignations were not the result of any disagreement with the company, its board, or management.
• · Mr. Zhang Chunming, aged 35, has nearly ten years of experience in corporate governance, risk management, compliance, and investment/financing advisory.
• · Mr. Ye Changkun, aged 42, has over ten years of professional experience in quality management, production operations, and team management.
• · The Audit Committee now comprises Wang Jinxiao (Chairman), Zhang Chunming, and Ye Changkun.
• · The Compensation Committee now comprises Zhang Chunming (Chairman), Wang Jinxiao, and Ye Changkun.
• · The Nomination Committee now comprises Wang Jinxiao (Chairman), Zhang Chunming, and Ye Changkun.
• · As a foreign private issuer, the company relies on the home country exemption under Nasdaq Listing Rule 5615(a)(3) and is not required to maintain a board comprising a majority of independent directors.

30-07-2026

WESCO International reported record second quarter 2026 net sales of $6.7 billion, up 13% YoY and 10% sequentially, driven by strong data center sales (+45% YoY to $1.5 billion) and record backlog (+60% YoY). Adjusted diluted EPS rose 35% YoY to a record $4.57, and adjusted EBITDA margin expanded 60 bps to 7.3%. However, operating cash flow declined 50% YoY to $54 million and free cash flow fell 63% to $32 million, reflecting higher working capital needs from sales growth and supplier prepayments.

• · Q2 2026 SG&A expenses rose 17.3% YoY to $1,022.7 million, driven by higher commissions, incentives, salaries, and benefits, plus $23.2 million in digital transformation costs.
• · Adjusted SG&A as a percentage of net sales increased to 15.0% in Q2 2026 from 14.6% in Q2 2025.
• · Interest expense increased $17.5 million in Q2 2026 due to higher net term debt, and a $10.0 million non-cash loss on extinguishment from redemption of 2028 Notes.
• · Gross margin improved 70 bps YoY to 21.8% in Q2 2026, driven by EES and CSS segments, partially offset by a decline in UBS segment.
• · The company raised its full-year 2026 outlook, citing favorable secular growth trends and confidence in continued execution.
• · Wesco acquired Singapore-based Newark Engineering to strengthen end-to-end capabilities and cooling solutions for data center customers.
• · Effective tax rate decreased 320 bps YoY to 22.9% in Q2 2026, largely due to higher discrete income tax benefits from stock-based awards.
• · Q2 2026 operating cash flow decline of $54.1 million was driven by a $182.8 million impact from changes in trade accounts receivable and a $155.3 million impact from other current and noncurrent assets, partially offset by a $129.9 million impact from changes in other current and noncurrent liabilities.

30-07-2026

Lincoln National Corp reported Q2 2026 net income of $1.3B ($6.72 per diluted share), up from $699M in Q2 2025, while adjusted operating income was $439M ($2.24 per share), slightly below the prior-year $427M ($2.36 per share). Life Insurance and Retirement Plan Services posted strong earnings growth, but Group Protection operating income declined 15% YoY and Annuities net outflows worsened to $2.9B from $1.2B. Holding company available liquidity net of prefunding rose to $903M, and the company completed a $500M subordinated debt issuance.

• · Holding company available liquidity (gross) was $1.803B as of June 30, 2026, up from $466M a year earlier.
• · RBC ratio remained above 420% for all quarters presented.
• · Book value per share including AOCI rose to $53.68 from $44.91 YoY.
• · Adjusted book value per share increased to $79.45 from $72.77 YoY.
• · Annuities average account balances reached a record $179B, up 12% YoY.
• · Retirement Plan Services ending account balances were a record $131B.
• · Life Insurance total margin increased 160 bps to 3.6%.
• · Group Protection total loss ratio increased 250 bps to 68.4% YoY, driven by experience refund recognition change.
• · Alternative investment income (after-tax) for Life Insurance dropped sharply to $38M in Q2 2026 from $74M in Q2 2025.
• · Consolidated alternative investment income (after-tax) fell to $41M in Q2 2026 from $80M in Q2 2025.

30-07-2026

ioneer Ltd filed a Form 6-K with the SEC for July 2026, attaching its Quarterly Report for the three months ended June 30, 2026. The filing was signed by CFO April Hashimoto. No specific financial figures or performance data are included in the cover filing itself, only the reference to the attached quarterly report.

• · The filing is a Form 6-K for the month of July 2026.
• · The attached exhibit is the Quarterly Report for the three months ended June 30, 2026.
• · The registrant's principal executive offices are at Suite 16.01, 213 Miller Street, North Sydney, NSW, 2060, Australia.
• · The registrant files annual reports under Form 20-F.

30-07-2026

British American Tobacco p.l.c. filed its Half-Year Report for the period ending June 30, 2026, via Form 6-K with the SEC on July 30, 2026. The report includes financial results for the first half of 2026, but no specific figures are provided in the filing itself. The filing also incorporates the report by reference into several existing registration statements.

• · The Half-Year Report is filed as Exhibit 1 to the Form 6-K.
• · The report is incorporated by reference into multiple Form S-8 and Form F-3 registration statements.
• · The filing is made under Commission File Number 001-38159.

30-07-2026

IperionX Limited filed a Form 6-K with the SEC on July 30, 2026, attaching its Quarterly Report for the quarter ended June 30, 2026. The filing is a routine foreign issuer report and does not contain any financial figures or performance data beyond the exhibit reference.

30-07-2026

Solstice Advanced Materials reported Q2 2026 net sales of $1,148 million, up 11% YoY, driven by double-digit growth in Nuclear (+27%), Electronic Materials (+15%), Refrigerants (+13%), and Healthcare Packaging (+24%). However, Adjusted EBITDA margin contracted 218 bps to 25.3% due to plant turnaround activity and prior-year production credits, and the Refrigerants & Applied Solutions segment saw Adjusted EBITDA decline 6% YoY. The company raised full-year 2026 guidance and announced the planned acquisition of Element Solutions, expected to close in H1 2027.

• · Building Solutions & Intermediates net sales declined 1% YoY to $180M.
• · Corporate expenses increased to $54M in Q2 2026 from $46M in Q2 2025 due to incremental standalone public company costs.
• · Income tax expense decreased to $42M in Q2 2026 from $101M in Q2 2025; effective tax rate dropped to 24% from 51%.
• · The company raised full-year 2026 net sales guidance to $4,125M-$4,185M (from $3,900M-$4,100M) and Adjusted EBITDA guidance to $1,035M-$1,055M (from $975M-$1,025M).
• · Q3 2026 net sales guidance is $990M-$1,030M.
• · Capital expenditures guidance for full-year 2026 raised to $420M-$440M (from $400M-$425M).
• · The company expects RAS segment to generate mid-30% Adjusted EBITDA margins in H2 2026.
• · Quarterly dividend of $0.075 per share declared, payable September 10, 2026.
• · The acquisition of Element Solutions is a cash-and-stock transaction subject to shareholder and regulatory approvals, expected to close in H1 2027.

30-07-2026

Quince Therapeutics, Inc. filed Amendment No. 2 to its Form 8-K to include audited financial statements of Orphai Therapeutics for the years ended December 31, 2025 and 2024, and unaudited interim financials for Q1 2026 and 2025, along with pro forma combined financial information. The filing also incorporates business and risk factor information of Orphai following the acquisition completed on May 17, 2026. No specific financial performance figures are disclosed in this amendment, so no period-over-period comparisons are available.

• · The acquisition of Orphai was completed on May 17, 2026.
• · Audited financial statements of Orphai are provided for years ended December 31, 2025 and 2024.
• · Unaudited interim condensed consolidated financial statements of Orphai are provided for the three months ended March 31, 2026 and 2025.
• · Unaudited pro forma condensed combined financial information of the Company is provided for the three months ended March 31, 2026 and the year ended December 31, 2025.
• · Retention bonus agreements were entered into with Dirk Thye and Brendan Hannah on May 17, 2026.
• · Employment letters with Brigette Roberts were effective May 18, 2026 (Company) and May 12, 2026 (Orphai).

30-07-2026

WTW reported Q2 2026 revenue of $2.47B, up 9% YoY (organic growth 5%), but net income fell 30% to $231M and diluted EPS dropped 27% to $2.43. Adjusted diluted EPS rose 17% to $3.35, and adjusted operating margin improved 100 bps to 19.5%. The company announced Propel, an AI acceleration plan targeting ~30% adjusted operating margin by 2028, and increased its share repurchase authority by $1.5B.

• · Career revenue within HWC was flat on an organic basis, constrained by the Middle East conflict.
• · Willis Re joint venture expected to be a ~$0.30 headwind on Adjusted Diluted EPS in 2026.
• · Newfront acquisition expected to be ~$0.10 dilutive to Adjusted EPS in 2026.
• · Foreign exchange expected to provide a ~$0.35 tailwind on Adjusted Diluted EPS for full-year 2026.
• · Company expects share repurchases of $1.0B or greater in 2026.
• · Propel plan targets ~$400M in run-rate savings with a cash-cost-to-achieve ratio of ~1.6x.
• · HWC segment operating margin improved only 30 bps to 24.1%.
• · R&B segment operating margin improved 100 bps to 22.2%.

30-07-2026

NanoViricides, Inc. announced a registered direct offering of approximately $3.8 million with a single institutional investor, issuing 2,516,339 shares of common stock (or pre-funded warrants) and accompanying warrants exercisable at $1.75 per share for five and a half years. The offering is expected to close on July 27, 2026, with D. Boral Capital LLC acting as placement agent. The company is a clinical-stage antiviral developer with its lead drug NV-387 having Orphan Drug Designation, but the offering dilutes existing shareholders and the company remains pre-revenue.

• · Each whole warrant has an exercise price of $1.75 per share and expires five and a half years from issuance.
• · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-296790), declared effective by the SEC on June 15, 2026.
• · NV-387 has Orphan Drug Designation from the FDA, potentially providing 7 years market exclusivity, tax credits, and fee exemptions upon approval.
• · NV-387 was found effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

30-07-2026

AITX announced via an 8-K filing on July 30, 2026, that its subsidiary RAD received its largest data center construction order to date. The filing includes a press release as an exhibit, but no financial terms or comparative performance data are disclosed.

• · The order is described as the largest data center construction order to date for RAD, AITX's subsidiary.
• · No specific dollar value, volume, or timeline for the order was disclosed in the filing.
• · The press release is attached as Exhibit 99.1 but its full content is not included in the 8-K text.

30-07-2026

Futurewave Acquisition Corporation announced that holders of its units may elect to separately trade the ordinary shares, rights, and warrants included in the units, commencing on or about July 31, 2026. The units not separated will continue to trade on the Nasdaq Capital Market under the symbol "FWACU," while the separated securities will trade under "FWAC," "FWACR," and "FWACW." This is a procedural update regarding the separability of the company's unit structure and does not involve any financial results or material changes in operations.

• · The separate trading of ordinary shares, rights, and warrants will commence on or about July 31, 2026.
• · Holders must contact their brokers to have Continental Stock Transfer & Trust Company separate the units.
• · The press release announcing the separate trading was issued on July 29, 2026, and is attached as Exhibit 99.1.

30-07-2026

Alterity Therapeutics Ltd filed a Form 6-K with the SEC on July 30, 2026, submitting its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter. The filing is a routine periodic disclosure by the Australian biotech development-stage enterprise, providing updates on operational and cash flow activities. No specific financial results or material events were detailed in the cover filing itself.

• · The filing incorporates by reference several existing SEC registration statements (Forms S-8 and F-3).
• · The company is classified as a development stage enterprise.
• · The report covers the month of July 2026 and was signed by Chairman Julian Babarczy.

30-07-2026

This is a Form 6-K filing by United Microelectronics Corporation (UMC) with the SEC on July 30, 2026, submitted by CFO Chitung Liu. The filing contains no financial results, operational updates, or specific material events beyond the routine submission of a foreign issuer report.

30-07-2026

Takeda reported Q1 FY2026 revenue of ¥1,219.9B, up 10.2% at actual exchange rates (AER) from ¥1,106.7B in Q1 FY2025, driven by strong growth in Europe (+19.1% AER), Latin America (+28.9% AER), and the Oncology segment (+19.4% AER). However, on a constant exchange rate (CER) basis, revenue declined 0.5% and net profit attributable to owners fell 8.9% AER (down 23.5% CER) to ¥113.2B, weighed by higher costs and expenses. Operating profit rose 9.1% AER to ¥201.4B but declined 3.1% CER, reflecting mixed underlying performance.

• · Cost of sales increased 5.7% AER to ¥406.7B (up 4.5% CER).
• · SG&A expenses rose 12.0% AER to ¥286.5B (up 1.6% CER).
• · R&D expenses increased 16.3% AER to ¥167.4B (up 6.8% CER).
• · Amortization and impairment losses on intangible assets associated with products decreased 15.7% AER to ¥110.9B (down 23.3% CER).
• · Other operating expenses surged 96.8% AER to ¥55.2B (up 73.4% CER).
• · Income tax expenses jumped 87.7% AER to ¥49.5B (up 71.7% CER).
• · Finance income and expenses, net increased 17.5% AER to ¥39.2B expense.
• · Japan revenue declined 3.8% AER (down 4.2% CER).
• · United States revenue grew 4.1% AER but declined 5.2% CER.
• · Rare Diseases segment revenue grew 4.9% AER but declined 5.8% CER.
• · PDT segment revenue grew 8.8% AER but declined 2.1% CER.
• · Neuroscience segment revenue grew 4.6% AER but declined 4.8% CER.
• · Other segment revenue declined 1.1% AER and 11.8% CER.
• · The filing includes condensed interim consolidated financial statements under IFRS and management's outlook for FY2027.
• · A conference call and earnings presentation were scheduled for July 30, 2026.

30-07-2026

Trane Technologies reported strong Q2 2026 results with organic bookings up 37% and a record backlog of $12.1 billion, up 70%. However, margins contracted across all segments: GAAP operating margin fell 100 bps to 19.3%, adjusted operating margin fell 60 bps to 19.7%, and adjusted EBITDA margin fell 70 bps to 21.1%. The EMEA segment was a notable weak spot, with revenues down 1% (organic -4%) and adjusted operating income down 26%. The company raised full-year 2026 revenue and EPS guidance.

• · Book-to-bill was 123% overall, led by Commercial HVAC across all regions.
• · Americas Commercial HVAC applied equipment bookings were up 130%.
• · EMEA segment revenues declined 1% reported and 4% organically, with GAAP operating income down 33% and adjusted operating income down 26%.
• · Asia Pacific segment GAAP operating margin declined 30 bps, adjusted operating margin declined 60 bps, and adjusted EBITDA margin declined 150 bps.
• · Year-to-date through July 2026, the company deployed or committed approximately $1.9 billion of capital: $690M for dividends, $340M for M&A, and $840M for share repurchases.
• · Full-year 2026 guidance raised: reported revenue growth ~11.5%, organic revenue growth ~9%, GAAP continuing EPS $15.00-$15.10, adjusted continuing EPS $15.20-$15.30.
• · Working capital/revenue improved to 0.9% from 3.7% a year ago, a 280 bps improvement.

30-07-2026

NOVAGOLD RESOURCES INC. filed a DEFA14A soliciting material on July 30, 2026, promoting a CNBC interview with Dr. Thomas S. Kaplan and Mr. John Paulson regarding a proposed transaction announced on July 22, 2026. The interview discusses long-term gold fundamentals, the strategic significance of the Donlin Gold project, and the alignment of the transaction with the company's strategy. The filing also includes extensive forward-looking statements and details about the upcoming proxy solicitation for shareholder approval of the transaction.

• · The filing is a DEFA14A (soliciting material) filed on July 30, 2026.
• · The proposed transaction was announced on July 22, 2026.
• · The interview was shared on LinkedIn and Facebook on July 29, 2026.
• · The proxy statement for the transaction will be filed with the SEC and Canadian securities regulators.
• · The transaction is subject to regulatory, shareholder, and court approvals.
• · No fee was required for this filing.

30-07-2026

Aerkomm Inc. reported a net income of $4.79M for Q1 2026, a significant turnaround from a net loss of $3.68M in Q1 2025, driven primarily by a non-cash gain on remeasurement of retained investment upon deconsolidation of $8.33M. However, operating expenses remained high at $2.88M, and the company continues to report a stockholders' deficit of $2.03M, though improved from $7.35M at year-end 2025. Cash increased to $171,742 from $55,285, but the company remains heavily reliant on debt and related-party payables.

• · Total assets increased to $86.18M from $69.97M, driven largely by a $19.4M increase in long-term investment.
• · Total liabilities rose to $88.21M from $77.32M, with other payable - related parties surging 784% to $11.51M.
• · The company reported a gain on remeasurement of retained investment upon deconsolidation of $8.33M, which was the primary driver of net income.
• · Operating cash flow turned positive at $196,315 compared to a use of $590,312 in the prior year period.
• · Inventories remained nearly flat at $968,754 vs $969,039.
• · Prepayment for land remains a significant asset at $40.33M, slightly down from $40.42M.
• · The company has a working capital deficit of $83.35M (current liabilities of $88.02M exceed current assets of $4.66M).
• · No revenue was reported for either period; the company is still in a pre-revenue stage.

30-07-2026

SoftVest Advisors, LLC, a 13.3% unitholder of Permian Basin Royalty Trust (PBT), has proposed a business combination between PBT and US Land Guild (USLG) valued at $2.2B. The transaction will create New PBT, a premier land and minerals platform, with PBT unitholders retaining 59.3% ownership and Blackbeard and affiliates holding 41%. The combination is expected to be accretive to PBT unitholders, with pro forma Q1 2026 annualized Adjusted EBITDA of $154.5M, up from $91.6M on a legacy PBT basis, though the transaction is subject to unitholder approval and regulatory filings.

• · The transaction is valued at $2.2B based on PBT unit price as of 7/27/26.
• · SoftVest beneficially owns approximately 13.3% of outstanding Trust Units.
• · The combination is expected to be accretive to PBT unitholders, with pro forma annualized Adjusted EBITDA of $154.5M vs. legacy PBT $91.6M.
• · PBT unitholders will retain 59.3% ownership; Blackbeard and affiliates will hold 41%.
• · The rights offering and private placement will raise $120M at a 12.5% discount to PBT unit price.
• · Pro forma leverage is 0.4x annualized Adjusted EBITDA.
• · Blackbeard Operating is currently running 4 rigs, averaging ~3 rigs across New PBT's position.
• · The transaction is subject to unitholder approval and SEC filings (Form S-4 registration statement).

30-07-2026

Galaxy Gaming, Inc. entered into a First Amendment to its Credit Agreement with BMO Bank N.A. on July 24, 2026, primarily to permit stock repurchases of up to $4.0 million using a $5.2 million termination fee from the now-terminated Evolution acquisition. The amendment also adjusts the Fixed Charge Coverage Ratio covenant to a minimum of 1.10x, effective from fiscal quarters ending on or about December 31, 2024, and updates financial reporting requirements. The amendment reflects the company's precautionary move following the expiration of the Evolution acquisition deadline on July 17, 2026, without a closing.

• · The Evolution Acquisition deadline was July 17, 2026, and the merger agreement was terminated after that date without closing.
• · The termination fee of $5,234,678 is the sole permitted source of funds for the stock repurchases.
• · The Fixed Charge Coverage Ratio covenant is set at a minimum of 1.10 to 1.0 for fiscal quarters ending on or about December 31, 2024, and thereafter.
• · The amendment requires the Borrower to maintain minimum Unencumbered Liquid Assets of $5,000,000 after any repurchase.
• · The stock repurchase authorization expires on January 6, 2028.

30-07-2026

MEXCO ENERGY CORP filed a 10-K/A on July 30, 2026, signed by Chairman/CEO Nicholas C. Taylor and President/CFO Tamala L. McComic. The filing includes certifications under Section 302 of the Sarbanes-Oxley Act and details equity compensation plans with 150,883 options outstanding and 68,500 shares remaining for future issuance.

• · The filing is an amendment (10-K/A) to the annual report.
• · Certifications under Section 302 of the Sarbanes-Oxley Act of 2002 are included for both CEO and CFO.
• · The 2009 Plan has no shares remaining for future issuance.
• · The 2019 Plan has 68,500 shares remaining for future issuance.

30-07-2026

Liminatus Pharma, Inc. disclosed in an 8-K filing that it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq. However, even if compliance is confirmed, Nasdaq will continue to monitor the company's ongoing compliance, and failure to evidence compliance in the next periodic report could lead to future delisting. The filing also includes cautionary forward-looking statements regarding the uncertainty of regaining or maintaining compliance.

• · The company is waiting for a compliance determination from Nasdaq regarding its stockholders' equity.
• · If compliance is not evidenced at the time of the next periodic report, the company may be subject to future delisting.
• · The filing includes forward-looking statements with no obligation to update them.

30-07-2026

California Water Service Group reported strong Q2 2026 results, with net income rising to $56.5M ($0.93/diluted share) from $42.2M ($0.71/diluted share) in Q2 2025, and revenue increasing to $308.6M from $265.0M, driven by resolution of the 2024 California General Rate Case (CA GRC). However, operating expenses grew to $237.7M from $213.1M, with water production costs up $6.3M and other operations expenses up $13.4M, partially offset by a $6.5M decrease in depreciation. The company also announced a record $147M infrastructure investment in the quarter and progress on the $218M acquisition of Nexus Water Group's Nevada and Oregon systems.

• · Depreciation and amortization expenses decreased by $6.5M in Q2 2026 and $2.5M YTD due to lower depreciation rates in California approved in the 2024 CA GRC.
• · Income taxes increased by $7.0M in Q2 2026 and $6.0M YTD due to a reduction in TCJA deferred accrued income tax amortization and higher pre-tax income.
• · IRMA revenue related to the delayed 2024 CA GRC added $15.3M in Q2 2026, of which $9.2M related to Q1 2026.
• · The company declared a quarterly dividend of $0.3350 per common share, payable August 21, 2026, reflecting an 8% annual increase to $1.34 per share.
• · The Nexus acquisition remains subject to regulatory approvals; Change of Control applications filed in Nevada and Oregon in April 2026.
• · In Texas, the change in control application has been deemed complete by the Public Utility Commission of Texas.

30-07-2026

AtaiBeckley Inc. (atai Life Sciences) is being acquired by Eli Lilly and Company for $6.75 per share in cash plus up to $2.50 per share in contingent value rights (CVRs) tied to milestone payments. Centerview Partners LLC has issued a fairness opinion concluding that the merger consideration is fair from a financial point of view to holders of common stock (excluding certain holders). The filing does not provide period-over-period financial comparisons, but the transaction represents a significant liquidity event for shareholders.

• · The merger consideration consists of $6.75 per share in cash plus one CVR per share representing up to $2.50 in milestone payments.
• · Centerview Partners LLC provided a fairness opinion dated July 15, 2026, stating the consideration is fair from a financial point of view to holders of Company Common Stock (excluding Excluded Holders).
• · Excluded Holders include shares held in treasury, owned by the Company or its subsidiaries, owned by Eli Lilly, Albali Acquisition Corporation, or any direct/indirect wholly owned subsidiary of the acquiror, and Dissenting Shares.
• · The filing references financial forecasts prepared by management, including assumptions about a proposed royalty financing transaction and other proposed equity financing.
• · The CVR Agreement includes milestones with probabilities and timing informed by management, used in Centerview's analysis.
• · No independent evaluation or appraisal of assets or liabilities was conducted by Centerview.

30-07-2026

Pilgrim Partners Asia Pte Ltd filed its Q2 2026 13F-HR with the SEC, reporting a portfolio of 108 equity holdings valued at approximately $234 million as of June 30, 2026. The fund's largest positions include iShares Bitcoin Trust ($60.7M), Invesco QQQ Trust ($40.2M), State Street SPDR S&P 500 ETF ($25.8M), and Vanguard S&P 500 ETF ($21.9M), reflecting a heavy tilt toward broad-market and crypto ETFs. No prior-period comparison is available in this filing, so performance trends cannot be assessed.

• · The portfolio includes 108 equity positions with a total market value of $233,999,325.
• · The largest single holding is iShares Bitcoin Trust ETF at $60.7M (1,822,300 shares), representing ~26% of the portfolio.
• · Other top holdings include Invesco QQQ Trust ($40.2M), State Street SPDR S&P 500 ETF ($25.8M), and Vanguard S&P 500 ETF ($21.9M).
• · The fund holds a put option on Strategy Inc. (5,800 shares) and call options on PDD Holdings (6,270 shares) and Teucrium Commodity Trust Sugar Fund (7,000 shares).
• · Notable positions include Interactive Brokers Group ($12.1M), Sandisk Corp ($4.5M), and Lumentum Holdings ($1.9M).
• · The fund has exposure to uranium and nuclear energy through Cameco, Centrus Energy, Global X Uranium ETF, and NuScale Power.
• · Other thematic holdings include rare earth (MP Materials, USA Rare Earth, Energy Fuels), defense (Kratos, L3Harris, Leonardo DRS), and crypto-related equities (MARA Holdings, Galaxy Digital).
• · No prior quarter comparison is available as this appears to be the filer's initial 13F filing.

30-07-2026

Anfield Energy Inc. filed a Form 6-K with the SEC for July 2026, incorporating by reference a Preliminary Economic Assessment (PEA) for its Shootaring Canyon Mill and Tributary Mines dated May 4, 2026, along with consents from technical experts Terrence McNulty and Douglas Beahm. The filing updates the company's registration statement on Form F-10. No financial results or period-over-period comparisons are provided in this filing.

• · The PEA is dated May 4, 2026.
• · The filing incorporates Exhibits 99.1, 99.2, and 99.3 into the Company's Registration Statement on Form F-10 (File No. 333-291078).
• · The registrant's address is 2005-4390 Grange Street, Burnaby, British Columbia, Canada, V5H 1P6.
• · The company files annual reports under Form 40-F.

30-07-2026

Aeluma, Inc. announced it has signed a Letter of Intent (LOI) with the U.S. Department of Commerce for up to $30 million in proposed funding under the CHIPS and Science Act to support R&D of its scalable, non-InP semiconductor manufacturing platform for photonics. The award is subject to further due diligence, approvals, and execution of definitive documents, with a portion funded upfront and the remainder milestone-based. The company would issue equity securities to the Department of Commerce equal to the award amount, and there is no guarantee the funding will be finalized.

• · The award is subject to further due diligence, required approvals (including internal U.S. Government approvals), and execution of definitive award documents.
• · The LOI contemplates a portion of the award funded upfront and the remainder on a milestone-based structure tied to eligible project costs and technical progress.
• · Aeluma would issue equity securities to the U.S. Department of Commerce with an aggregate value equal to the award amount.
• · Aeluma's platform uses large-diameter, mismatched substrates up to 300mm in size.
• · The company has a history of losses and limited operating history.
• · The press release includes forward-looking statements and risk factors regarding the uncertainty of finalizing the award.

30-07-2026

Endeavour Silver Corp. filed an amendment (Form 6-K/A) to its Foreign Issuer Report to incorporate by reference its condensed consolidated interim financial statements and management's discussion and analysis for the period ended June 30, 2026, into its registration statement on Form F-10. The filing includes CEO and CFO certifications. No specific financial figures or performance metrics are disclosed in this amendment.

• · This is an amendment (No. 1) to the original Form 6-K filed on July 29, 2026.
• · The amendment incorporates Exhibits 99.1 and 99.2 into the registrant's Form F-10 registration statement (No. 333-287602).
• · Exhibits 99.3 and 99.4 are Form 52-109F2 certifications by the CEO and CFO, respectively.

30-07-2026

MiMedx Group announced an agreement to acquire Sanara MedTech, combining their regenerative product portfolios across surgical and wound care markets. The transaction is expected to close by the end of the year, subject to customary closing conditions, and both companies will continue to operate separately until then. No financial terms or performance metrics were disclosed in this communication.

• · The acquisition is expected to close by the end of the year, subject to customary closing conditions.
• · MiMedx will file a registration statement on Form S-4 with the SEC, including a proxy statement/prospectus for Sanara stockholders.
• · Investors and security holders are urged to read the proxy statement/prospectus and other relevant documents when available.
• · Participants in the solicitation include directors and executive officers of both companies; their interests are described in prior proxy statements.

30-07-2026

McBroom & Associates, LLC filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a portfolio value of approximately $198.9 million across 37 equity positions. The filing shows a concentrated, long-only equity portfolio with top holdings in Lam Research ($24.0M), NVIDIA ($17.9M), and O'Reilly Automotive ($10.2M). No prior-period comparison data is available in this filing, so period-over-period changes cannot be assessed.

• · Largest holding: Lam Research Corp at $24,007,641 (55,403 shares).
• · Second largest: NVIDIA Corporation at $17,934,667 (89,633 shares).
• · Third largest: JPMorgan Chase & Co at $10,425,788 (31,851 shares).
• · Smallest positions include Coca-Cola Co ($325,080) and US Bancorp ($214,722).
• · Portfolio includes 8 ETFs/trusts (iShares, SPDR, Schwab, J.P. Morgan, EA Series, Dimensional).
• · No options, warrants, or convertible securities reported; all positions are common stock.

30-07-2026

WJ Interests, LLC filed its institutional holdings report (13F-HR) for the period ended June 30, 2026, disclosing a portfolio of approximately $259,360,277 across 22 equity positions. The fund's largest positions include the Return Stacked Global Stocks ETF, the Schwab High-Yield Bond ETF, and the Vanguard Total World Stock ETF, with no current-period comparisons available.

• · Top holdings based on market value: Return Stacked Global Stocks ETF ($52,475,825), Return Stacked Bonds & Stocks ETF ($52,475,825? — actually $11,893,487 from Tidal Trust II), Vanguard Total World Stock ETF ($37,980,363), and American Century U.S. Large Cap Value ETF ($22,465,525).
• · Largest single stock holdings: Microsoft Corp. ($210,010), JPMorgan Chase & Co. ($1,145,000), and IBM ($411,129).
• · All positions are held with sole voting and dispositive power.

30-07-2026

Elroy Air, a developer of autonomous heavy-cargo drones, announced three new unattended delivery modes for its Chaparral drone under a U.S. Army contract, including precision airdrop from hover, forward flight, and ground delivery. The company is also pursuing a business combination with Columbus Circle Capital Corp II (Nasdaq: CMII) to become publicly traded as Inflection Point Acquisition Corp VII. While the new capabilities demonstrate technical progress and military interest, the filing contains no financial data, and the company's demand pipeline consists of non-binding letters of intent that may not convert to revenue.

• · Demonstration occurred on July 15, 2026 at Elroy Air's Byron, California headquarters.
• · Kratos Defense & Security Solutions will manufacture Chaparral aircraft under a U.S. manufacturing partnership, announced July 20, 2026.
• · The business combination will rename Columbus Circle Capital Corp II to Inflection Point Acquisition Corp VII (Nasdaq: IPXG).
• · Elroy Air's demand pipeline consists of non-binding letters of intent and memorandums of understanding, with no assurance of conversion to binding orders or future revenue.

30-07-2026

Highway Holdings Limited (Nasdaq: HIHO) declared a cash dividend of $0.05 per common share, to be paid on September 22, 2026 to shareholders of record on August 10, 2026 (updated from August 8). The company's CEO stated that the dividend reflects a strengthened financial position and confidence in the future, noting the company has reached an inflection point. No financial results or period-over-period comparisons were provided in this filing.

• · Dividend record date was updated from August 8, 2026 to August 10, 2026.
• · The company's manufacturing facilities are located in Germany, Yangon, Myanmar, and Shenzhen, China.
• · Blue chip equipment manufacturers based primarily in Germany are the company's main customers.

30-07-2026

Diversify Wealth Management, LLC filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a total of 1,286 positions with aggregate market value of approximately $5.98 billion. The filing shows a concentrated portfolio with top holdings in Apple Inc. ($151.3M), Amazon.com Inc. ($79.5M), Alphabet Inc. (Class A & C combined ~$126.2M), and Advanced Micro Devices Inc. ($56.7M). The firm also holds significant put option positions on Apple (130,100 shares) and call options on several names, indicating active hedging and directional strategies.

• · The filing includes 1,286 positions with a total market value of $5,983,346,843.
• · Top equity holdings include Apple Inc. ($151.3M), Amazon.com Inc. ($79.5M), Alphabet Inc. Class A ($63.0M), Alphabet Inc. Class C ($63.3M), and Advanced Micro Devices Inc. ($56.7M).
• · The firm holds a significant put option on Apple Inc. covering 130,100 shares with a market value of $438,320.
• · Other option positions include call options on AbbVie Inc., Adobe Inc., Amgen Inc., ASML Holding NV, AT&T Inc., and Blackstone Inc., and put options on Adobe Inc., Alphabet Inc. Class C, Amazon.com Inc., Blackstone Inc., and Block Inc.
• · The filing was signed by Lupe Fungalei, Compliance Analyst, on July 29, 2026.
• · The report is for the period ending June 30, 2026, filed on July 30, 2026.